Our lab uses integrated approaches including genetics, cell biology, and bioinformatic tools to increase our understanding of the biological components of cerebral cavernous malformations (CCMs) and neuroinflammation. CCMs are brain vascular malformations prone to repetitive hemorrhagic stroke, which cause neurological deficit and occasionally death in ~0.5% of the population. Currently no pharmacological therapy exists for those afflicted. Our research has demonstrated that mild angiogenesis inhibitors including thrombospondin1 derivatives may provide a novel opportunity to treat CCMs. In addition, our research has pioneered the important role of endothelial microRNAs as regulators of cerebrovascular integrity during health and neuroinflammation. The ultimate goal of our research is to provide non-invasive, safe, and effective therapies to cardiovascular and neurological diseases.